The CD73/AXL.HypoSti.CAR-T cell therapy represents a novel approach in the CAR-T landscape, specifically targeting advanced/metastatic solid tumors, a segment with significant unmet medical need. The dual targeting of CD73 and AXL aims to overcome challenges associated with tumor heterogeneity and immunosuppressive microenvironments. Given the increasing interest in CAR-T therapies for solid tumors, successful outcomes could position this asset favorably against existing therapies, potentially capturing market share in a competitive landscape. The trial is sponsored by the Chinese PLA General Hospital, with collaboration from Fudan University, indicating strong institutional backing. However, the asset is currently not FDA-regulated, which may limit its initial market access outside China.